Galatea Bio
Biobank consented samples with associated clinical data from diverse populations from throughout the United States and Latin America via healthcare and biopharma partnerships.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $25.0m | Early VC | |
| Total Funding | 000k | ||
Related Content
Galatea Bio is a pioneering company in the field of genomics, focusing on precision health solutions by leveraging diverse genomic datasets. The company aims to address the underrepresentation of minority populations in genomic research, which has traditionally focused on northern European communities. By expanding the diversity of the dataset, Galatea Bio seeks to accelerate the discovery rate in genomics and narrow the gap in health outcomes for underrepresented minorities.
Galatea Bio operates in the healthcare and biotechnology market, serving clients such as clinical labs, pharmaceutical companies, and research institutions. The business model revolves around three core offerings: GB Community, GB Discovery, and GB Health. GB Community focuses on biobanking with an emphasis on diversity, starting with the Biobank of the Americas. GB Discovery leverages the data from GB Community to develop new algorithms and pharmaceutical targets. GB Health aims to build a clinical lab that delivers actionable results to partners in the clinic and pharma sectors.
The company generates revenue through partnerships, research collaborations, and providing genomic data and insights to its clients. By focusing on the unique genetic makeup of minorities, Galatea Bio aims to uncover novel genetic associations that can lead to the development of new drugs and therapies.
Keywords: genomics, precision health, diverse datasets, biobanking, pharmaceutical targets, clinical lab, minority health, genetic research, health outcomes, personalized medicine.